Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy Kelly C. Young-Wolff, PhD, MPH; Varada Sarovar, PhD; Lue-Yen Tucker, BA; Nancy C. Goler, MD; Stacey E. Alexeeff, PhD; Kathryn K. Ridout,MD, PhD; Lyndsay A. Avalos, PhD JAMA Network Open, 2020, 3, (2), e1921333. doi : 10.1001/jamanetworkopen.2019.21333 Introduction Prenatal cannabis use is increasing,1,2 and several qualitative studies3,4 indicate that pregnantwomen self-report using cannabis to manage stress and mood. However, few epidemiological studies have examined whether pregnant women with mental health disorders and trauma are at increased risk of using cannabis during pregnancy. Data from the Kaiser Permanente Northern California (KPNC) large integrated health care [...]
Lire la suiteCanada : La consommation de cannabis des 15-17 ans a baissé de 47% depuis la légalisation Newsweed, 20 février 2020 Par Aurélien BERNARD Depuis la légalisation du cannabis au Canada en octobre 2018, Statistique Canada, l’organe statistique national, conduit tous les 3 mois une enquête pour récolter des données sur la consommation de cannabis des Canadiens. Malgré les limites inhérentes au déclaratif, ces données permettent d’entrevoir les effets de la légalisation sur les Canadiens. Consommation de cannabis selon l’âge Ainsi, après un an de légalisation, plus de 5,1 millions de Canadiens de 15 ans ou plus ont déclaré avoir consommé du cannabis en 2019 au cours [...]
Lire la suiteThe epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, Robert M. Grant, and Elise Renn Journal of Psychopharmacology, 2018, 32, (7), 779–792. doi : 10.1177/0269881118769063 Abstract Background/Aim : 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, Toad, and Plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences [...]
Lire la suitePsilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734 Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]
Lire la suiteRisk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation Among Adolescents Jessica L. Barrington-Trimis, PhD; Junhan Cho, PhD; Esthelle Ewusi-Boisvert, BA; Deborah Hasin, PhD; Jennifer B. Unger, PhD; Richard A. Miech, PhD; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (1), e1919792. doi : 10.1001/jamanetworkopen.2019.19792 Abstract IMPORTANCE : While a diverse array of cannabis products that may appeal to youth is currently available, it is unknown whether the risk of persistent cannabis use and progression to higher frequency of use after experimentation differs among cannabis products. OBJECTIVE : To estimate the comparative relative risk of experimental use of 5 cannabis products [...]
Lire la suiteThe health and social effects of nonmedical cannabis use World Health Organization, 2016. CONTENTS Foreward. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . v Acknowledgements .. . . . . . . . . . . . . . . . . . . [...]
Lire la suiteAssociation Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016 Magdalena Cerdá, DrPH; Christine Mauro, PhD; Ava Hamilton, BA; Natalie S. Levy, MPH; Julián Santaella-Tenorio, DrPH; Deborah Hasin, PhD; Melanie M.Wall, PhD; Katherine M. Keyes, PhD; Silvia S. Martins, MD, PhD JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.3254 IMPORTANCE : Little is known about changes in marijuana use and cannabis use disorder (CUD) after recreational marijuana legalization (RML). OBJECTIVES : To examine the associations between RML enactment and changes in marijuana use, frequent use, and CUD in the United States from 2008 to 2016. DESIGN, SETTING, AND [...]
Lire la suiteAssociations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review Divya Ravi, MD, MPH; Mehrnaz Ghasemiesfe, MD; Deborah Korenstein, MD; Thomas Cascino, MD; and Salomeh Keyhani, MD, MPH Annals of Internal Medicine, 2018, 168, (3), 187-194. doi : 10.7326/M17-1548 Annals.org Abstract Background : Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. Purpose : To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. Data Sources : PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between 1 January 1975 and 30 September 2017. Study Selection : Observational studies that were published [...]
Lire la suiteStroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes Rupak Desai, Sandeep Singh, Krupa Patel, Hemant Goyal, Manan Shah, Zeeshan Mansuri, Smit Patel, Zabeen K Mahuwala, Larry B Goldstein and Adnan I Qureshi International Journal of Stroke, 2019, doi: 10.1177/1747493019895651 Abstract BACKGROUND : Recent legalization of therapeutic and recreational cannabis use makes it imperative to have an insight into odds and trends in young-onset stroke-related hospitalizations among cannabis users (18-49 years). METHODS : The National Inpatient Sample dataset (2007-2014) was utilized to assess national trends, odds of young-onset stroke-related hospitalizations, and outcomes among cannabis users vs. nonusers using provided discharge weights, [...]
Lire la suiteDriving Under the Influence of Marijuana and Illicit Drugs Among Persons Aged ≥16 Years — United States, 2018 Alejandro Azofeifa, DDS; Bárbara D. Rexach-Guzmán, MPH; Abby N. Hagemeyer, PhD; Rose A. Rudd, MSPH; Erin K. Sauber-Schatz, PhD Morbidity and Mortality Weekly Report, 2019, 68, (50), 1153-1157. https://www.medscape.com/viewarticle/923059?nlid=133476_425&src=WNL_mdplsfeat_200114_mscpedit_psyc&uac=292598PZ&spon=12&impID=2244648&faf=1 Abstract and Introduction Introduction In the United States, driving while impaired is illegal. Nonetheless, an estimated 10,511 alcohol-impaired driving deaths occurred in 2018.* The contribution of marijuana and other illicit drugs to these and other impaired driving deaths remains unknown. Data from the Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health (NSDUH) indicated [...]
Lire la suite